Home LiteratureArticle Details
PMID: 2690818 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

The Biochemical journal ·Vol. 264 ·No. 1 ·1989-11-15 ·Pages 1-14

Morgan BP

Abstract

暂无摘要

MeSH Terms
Calcium/physiology Cell Physiological Phenomena Cell Survival Complement Activation Complement Membrane Attack Complex/physiology Disease Erythrocytes/physiology Eukaryotic Cells/physiology Humans Neutrophils/physiology Species Specificity
Chemicals
Complement Membrane Attack Complex Calcium
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Morgan B P
Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff, U.K.
References (131)
131 references, click to expand
  1. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
    J Immunol. 1986 Mar 1;136(5):1772-6 PMID: 2419413
  2. Effect of fatty acid modifications of cultured hepatoma cells on susceptibility to complement-mediated cytolysis.
    Cancer Res. 1980 Apr;40(4):1084-90 PMID: 7357539
  3. Size distribution and stability of the trans-membrane channels formed by complement complex C5b-9.
    Mol Immunol. 1983 Feb;20(2):155-60 PMID: 6302478
  4. Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components.
    J Immunol. 1984 Oct;133(4):2145-50 PMID: 6432907
  5. Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+.
    J Immunol. 1986 Jul 1;137(1):263-70 PMID: 3711667
  6. Prelytic reduction of high-energy phosphates induced by antibody and complement in nucleated cells. 31P-NMR study.
    Complement. 1984;1(4):207-12 PMID: 6544190
  7. Free-radical mechanisms in tissue injury.
    Biochem J. 1984 Aug 15;222(1):1-15 PMID: 6383353
  8. G protein involvement in receptor-effector coupling.
    J Biol Chem. 1988 Feb 25;263(6):2577-80 PMID: 2830256
  9. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense.
    Crit Rev Immunol. 1981 Jan;1(3):165-209 PMID: 6174273
  10. Non-lethal complement-membrane attack on human neutrophils: transient cell swelling and metabolic depletion.
    Immunology. 1988 Jan;63(1):71-7 PMID: 3338820
  11. Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis.
    Arthritis Rheum. 1986 Nov;29(11):1359-64 PMID: 3778542
  12. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
    Biochemistry. 1984 Aug 28;23(18):4016-22 PMID: 6487588
  13. Relationship between the intracellular cyclic adenosine 3':5'-monophosphate level of tumor cells and their sensitivity to killing by antibody and complement.
    Cancer Res. 1979 Aug;39(8):3156-62 PMID: 222445
  14. The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium.
    Biochem J. 1985 Oct 1;231(1):205-8 PMID: 4062885
  15. In vivo and in vitro evidence of cell recovery from complement attack in rheumatoid synovium.
    Clin Exp Immunol. 1988 Sep;73(3):467-72 PMID: 3208453
  16. How do inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate regulate intracellular Ca2+?
    Biochem Soc Trans. 1989 Feb;17(1):6-9 PMID: 2535674
  17. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement.
    Nature. 1989 Jun 22;339(6226):620-2 PMID: 2733792
  18. Paroxysmal nocturnal hemoglobinuria. Enhanced stimulation of platelets by the terminal complement components is related to the lack of C8bp in the membrane.
    J Immunol. 1988 May 1;140(9):3045-51 PMID: 3361126
  19. Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77.
    J Immunol. 1983 Mar;130(3):1345-9 PMID: 6600482
  20. LESIONS IN ERYTHROCYTE MEMBRANES CAUSED BY IMMUNE HAEMOLYSIS.
    Nature. 1964 Apr 18;202:251-2 PMID: 14167777
  21. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis.
    J Immunol. 1987 Jan 1;138(1):246-53 PMID: 3782799
  22. Single channel currents induced by complement in antibody-coated cell membranes.
    Proc Natl Acad Sci U S A. 1981 Oct;78(10):6421-5 PMID: 6273870
  23. Correlation between lipid synthesis in tumor cells and their sensitivity to humoral immune attack.
    Science. 1977 Aug 19;197(4305):773-6 PMID: 196331
  24. Modulation of tumor cell susceptibility to humoral immune killing through chemical and physical manipulation of cellular lipid and fatty acid composition.
    J Immunol. 1980 Sep;125(3):1196-200 PMID: 7410835
  25. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  26. The role of polyphosphoinositides and their breakdown products in A23187-induced release of arachidonic acid from rabbit polymorphonuclear leucocytes.
    Biochem J. 1986 Sep 1;238(2):425-36 PMID: 3026352
  27. Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes.
    J Immunol. 1986 Aug 15;137(4):1286-93 PMID: 2426360
  28. Heymann antibodies induce complement-dependent injury of rat glomerular visceral epithelial cells.
    J Immunol. 1987 Nov 1;139(9):2906-14 PMID: 3312408
  29. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9.
    J Immunol. 1985 Mar;134(3):1804-9 PMID: 3968432
  30. Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack.
    Nature. 1985 Sep 12-18;317(6033):164-6 PMID: 4033797
  31. Adenosine 3'5'-monophosphate: inhibition of complement-mediated cell lysis.
    Science. 1974 Feb 15;183(4125):659-61 PMID: 4129650
  32. Expression of H-2 and Moloney leukemia virus-determined cell-surface antigens in synchronized cultures of a mouse cell line.
    Proc Natl Acad Sci U S A. 1971 Mar;68(3):566-9 PMID: 5276763
  33. Microvascular deposition of complement membrane attack complex in dermatomyositis.
    N Engl J Med. 1986 Feb 6;314(6):329-34 PMID: 3945256
  34. Cell growth-dependent variation in the sensitivity of human and mouse tumor cells to complement-mediated killing.
    Cancer Res. 1983 Feb;43(2):491-5 PMID: 6401218
  35. Mechanisms of tissue damage by the membrane attack complex of complement.
    Complement Inflamm. 1989;6(2):104-11 PMID: 2656078
  36. Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis.
    J Immunol. 1975 Aug;115(2):473-5 PMID: 50364
  37. Complement-mediated production of plasma-membrane vesicles from rat fat-cells.
    Biochem J. 1980 Mar 15;186(3):897-906 PMID: 6249263
  38. Studies on the mechanism of superoxide release from human neutrophils stimulated with arachidonate.
    J Biol Chem. 1984 Oct 10;259(19):11851-7 PMID: 6090448
  39. Structural alterations in the surface membrane during the cell cycle.
    J Cell Biol. 1971 Aug;50(2):562-4 PMID: 4107022
  40. Life-span and size of the trans-membrane channel formed by large doses of complement.
    J Immunol. 1980 May;124(5):2281-7 PMID: 6245139
  41. The action of antibody and complement on mammalian cells.
    Ann N Y Acad Sci. 1960 May 31;87:352-62 PMID: 13851487
  42. On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity.
    J Biol Chem. 1986 Nov 5;261(31):14587-92 PMID: 3155419
  43. Membrane attack complex of complement in dermatitis herpetiformis.
    Arch Dermatol. 1985 Jan;121(1):70-2 PMID: 3881089
  44. Lysis of tumor cells by antibody and complement. II. Lack of correlation between amount of C4 and C3 fixed and cell lysis.
    J Immunol. 1975 Apr;114(4):1292-5 PMID: 163862
  45. Prostaglandins and leukotrienes as inflammatory mediators.
    Br Med Bull. 1987 Apr;43(2):285-96 PMID: 2825898
  46. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex.
    J Neurol Sci. 1987 Mar;78(1):17-28 PMID: 3572448
  47. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels.
    J Biochem. 1988 Oct;104(4):633-7 PMID: 2467907
  48. Quantitative studies of the sensitivity of normal and neoplastic mouse cells to the cytotoxic action of isoantibodies.
    J Exp Med. 1962 Mar 1;115:527-53 PMID: 14475217
  49. Immunohistochemical detection of the terminal C5b-9 complement complex in children with glomerular diseases.
    Clin Exp Immunol. 1986 Jul;65(1):66-72 PMID: 3539428
  50. 2-Chloroadenosine inhibits complement-induced reactive oxygen metabolite production and recovery of human polymorphonuclear leucocytes attacked by complement.
    Biochem Biophys Res Commun. 1985 Jan 31;126(2):692-7 PMID: 3977885
  51. An antigen density effect on the hemolytic efficiency of complement.
    J Immunol. 1970 May;104(5):1307-9 PMID: 4192162
  52. Some aspects of the ascites tumor cell response to a heterologous antiserum.
    Cancer Res. 1958 Nov;18(10):1179-85 PMID: 13596961
  53. Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes.
    J Neurochem. 1987 Jan;48(1):271-8 PMID: 3025367
  54. Ability of tumor cells to resist humoral vs. cell-mediated immune attack is controlled by different membrane physical properties.
    Biochem Biophys Res Commun. 1982 May 14;106(1):58-64 PMID: 6809001
  55. Complement pores in erythrocyte membranes. Analysis of C8/C9 binding required for functional membrane damage.
    Biochim Biophys Acta. 1983 Aug 10;732(3):541-52 PMID: 6871214
  56. Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranolysis.
    Proc Natl Acad Sci U S A. 1979 Mar;76(3):1410-4 PMID: 220614
  57. Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology.
    Scand J Immunol. 1987 Oct;26(4):381-6 PMID: 3685888
  58. Activation of glomerular mesangial cells by the terminal membrane attack complex of complement.
    J Immunol. 1987 Apr 15;138(8):2473-80 PMID: 3494069
  59. Antigenic expression of a murine lymphoma during growth in vitro.
    Nature. 1970 Feb 14;225(5233):645-7 PMID: 5413373
  60. Failure of terminal complement components to induce lysis of Moloney virus transformed lymphocytes.
    J Immunol. 1974 Feb;112(2):866-8 PMID: 4855965
  61. Electrical measurements of complement-mediated membrane damage in cultured nerve and muscle cells.
    J Immunol. 1979 Feb;122(2):455-8 PMID: 762431
  62. Studies on the terminal stages of complement lysis.
    Immunology. 1973 Jan;24(1):135-45 PMID: 4346598
  63. Rapid increase in intracellular free Ca2+ induced by antibody plus complement.
    FEBS Lett. 1979 Nov 1;107(1):55-60 PMID: 227745
  64. Possible involvement of terminal complement complex in active Heymann nephritis.
    Kidney Int. 1985 Feb;27(2):388-93 PMID: 3886996
  65. Measurement of intracellular calcium ions and oxygen radicals in polymorphonuclear leucocyte-erythrocyte 'ghost' hybrids.
    J Physiol. 1983 May;338:537-50 PMID: 6410060
  66. Evidence for sequential signals in the induction of the arachidonic acid cascade in macrophages.
    J Exp Med. 1986 Jan 1;163(1):139-54 PMID: 2416865
  67. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells.
    J Clin Invest. 1986 Mar;77(3):762-7 PMID: 3005365
  68. Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives.
    Proc Natl Acad Sci U S A. 1983 Nov;80(21):6647-51 PMID: 6415654
  69. Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid.
    J Immunol. 1978 Feb;120(2):463-71 PMID: 202652
  70. Complement lysis of nucleated cells: effect of temperature and puromycin on the number of channels required for cytolysis.
    Mol Immunol. 1984 Nov;21(11):1015-21 PMID: 6096699
  71. Proteolytic modification of human complement protein C9: loss of poly(C9) and circular lesion formation without impairment of function.
    Proc Natl Acad Sci U S A. 1985 Apr;82(7):2128-32 PMID: 3885222
  72. The complement membrane attack complex stimulates the prostanoid production of cultured glomerular epithelial cells.
    Int Arch Allergy Appl Immunol. 1988;85(1):87-93 PMID: 3123397
  73. Intracellular free calcium as a pathogen in cell damage initiated by the immune system.
    Experientia. 1981 Oct 15;37(10):1110-2 PMID: 7308407
  74. The role of arachidonic acid oxygenation products in pain and inflammation.
    Annu Rev Immunol. 1984;2:335-57 PMID: 6100476
  75. Direct measurement of the increase in intracellular free calcium ion concentration in response to the action of complement.
    Biochem J. 1981 Feb 15;194(2):551-60 PMID: 6272733
  76. Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca++ -dependent exocytotic elimination of C5b-9 pores.
    Blood. 1986 Aug;68(2):556-61 PMID: 3730616
  77. The action of cytotoxic antisera on the HeLa strain of human carcinoma.
    Cancer Res. 1956 May;16(4):306-12 PMID: 13316756
  78. Stimulation of Ca2+-dependent chemiluminescence in rat polymorphonuclear leucocytes by polystyrene beads and the non-lytic action of complement.
    Immunology. 1981 Nov;44(3):569-76 PMID: 7319554
  79. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis.
    J Neuropathol Exp Neurol. 1980 Mar;39(2):160-72 PMID: 7373347
  80. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1.
    Clin Exp Immunol. 1988 Jun;72(3):422-7 PMID: 3262460
  81. Membrane attack complex of complement as a pathologic mediator.
    Lab Invest. 1983 Sep;49(3):237-49 PMID: 6193330
  82. Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis.
    J Immunol. 1986 Jun 15;136(12):4456-9 PMID: 3711661
  83. Immunohistochemical analysis of C3 cleavage fragments, factor H, and the C5b-9 terminal complex of complement in de novo membranous glomerulonephritis occurring in patients with renal transplant.
    Clin Nephrol. 1986 Oct;26(4):203-8 PMID: 2946502
  84. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
    Immunology. 1988 Apr;63(4):585-90 PMID: 3366469
  85. Structural changes produced in Brown-Pearce carcinoma cells by means of a specific antibody and complement.
    J Exp Med. 1953 Jan;97(1):145-62 PMID: 13022870
  86. Thromboxane B2 synthesis in human platelets induced by the late complement components C5b-9.
    Int Arch Allergy Appl Immunol. 1987;82(3-4):313-6 PMID: 2437045
  87. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.
    J Clin Invest. 1987 Nov;80(5):1492-7 PMID: 3680509
  88. Persistence of immunoglobulin and complement components C4 and C3 bound to guinea pig tumor cells.
    J Natl Cancer Inst. 1976 Jul;57(1):145-50 PMID: 187759
  89. Cytoskeletal and morphologic impact of cellular oxidant injury.
    Am J Pathol. 1986 Jun;123(3):454-64 PMID: 3717299
  90. Interaction of histocompatibility (HL-A) antibodies and complement with synchronized human lymphoid cells in continuous culture.
    J Exp Med. 1973 Jan 1;137(1):55-68 PMID: 4734592
  91. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium.
    J Immunol. 1986 Sep 15;137(6):1945-9 PMID: 3528291
  92. Molecular interactions of cells with antibody and complement: influence of metabolic and physical properties of the target on the outcome of humoral immune attack.
    Contemp Top Mol Immunol. 1978;7:153-80 PMID: 215378
  93. The cytotoxic action of immune gamma globulin and complement on Krebs ascites tumor cells. I. Ultrastructural studies.
    J Exp Med. 1959 May 1;109(5):505-10 PMID: 13641573
  94. Measurement of terminal complement complexes in rheumatoid arthritis.
    Clin Exp Immunol. 1988 Sep;73(3):473-8 PMID: 3208454
  95. Correlation between the ability of tumor cells to incorporate specific fatty acids and their sensitivity to killing by a specific antibody plus guinea pig complement.
    J Natl Cancer Inst. 1978 Sep;61(3):931-4 PMID: 278869
  96. The membrane attack complex of complement at the endplate in myasthenia gravis.
    Ann N Y Acad Sci. 1987;505:326-32 PMID: 3318619
  97. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.
    Immunochemistry. 1969 May;6(3):405-19 PMID: 5786934
  98. Immune cytolysis in relation to the growth cycle of Chinese hamster cells.
    Cancer Res. 1971 Jul;31(7):925-9 PMID: 5560386
  99. Release of leukotrienes from guinea pig lung stimulated by C5ades Arg anaphylatoxin.
    J Immunol. 1982 May;128(5):2247-52 PMID: 6174625
  100. Role of complement C9 and calcium in the generation of arachidonic acid and its metabolites from rat polymorphonuclear leukocytes.
    Mol Immunol. 1987 Dec;24(12):1263-71 PMID: 2828929
  101. Complement sensitivity of somatic hybrids of a complement-resistant murine leukemia cell line.
    J Natl Cancer Inst. 1975 Aug;55(2):309-17 PMID: 51086
  102. Oxygen toxicity, oxygen radicals, transition metals and disease.
    Biochem J. 1984 Apr 1;219(1):1-14 PMID: 6326753
  103. Induction of expression of cell-surface homologous restriction factor upon anti-CD3 stimulation of human peripheral lymphocytes.
    Proc Natl Acad Sci U S A. 1988 Jan;85(1):213-7 PMID: 2963326
  104. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex.
    Arthritis Rheum. 1986 Jun;29(6):715-21 PMID: 3718564
  105. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis.
    Lancet. 1984 Aug 4;2(8397):251-4 PMID: 6146808
  106. Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics.
    Proc Natl Acad Sci U S A. 1983 Jun;80(12):3816-20 PMID: 6602341
  107. Effect of metabolic inhibitors on killing of tumor cells by antibody and complement.
    J Natl Cancer Inst. 1974 Nov;53(5):1411-3 PMID: 4372384
  108. Nucleated cell killing by complement: effects of C5b-9 channel size and extracellular Ca2+ on the lytic process.
    J Immunol. 1987 Mar 1;138(5):1530-6 PMID: 2433349
  109. Is the primary complement lesion insufficient for lysis? Failure of cells damaged under osmotic protection to lyse in EDTA or at low temperature after removal of osmotic protection.
    Clin Immunol Immunopathol. 1975 May;4(1):108-26 PMID: 805009
  110. Elimination of complement channels from the plasma membranes of U937, a nucleated mammalian cell line: temperature dependence of the elimination rate.
    J Immunol. 1983 Sep;131(3):1411-5 PMID: 6309963
  111. Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus.
    J Immunol. 1987 Apr 1;138(7):2095-9 PMID: 3559203
  112. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.
    Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975-9 PMID: 2428045
  113. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis.
    Atherosclerosis. 1987 May;65(1-2):1-11 PMID: 2955791
  114. Variation in susceptibility of a human lymphoid cell line to immune lysis during the cell cycle. Lack of correlation with antigen density and complement binding.
    J Exp Med. 1974 Aug 1;140(2):578-90 PMID: 4527075
  115. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.
    Clin Exp Immunol. 1987 Nov;70(2):417-24 PMID: 3427827
  116. Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy.
    J Rheumatol. 1986 Dec;13(6):1028-34 PMID: 3550070
  117. Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. II. Inhibition of transformation of T to dead cells by 3'5' cAMP.
    J Immunol. 1976 May;116(5):1276-9 PMID: 178794
  118. Cell cycle-dependent immune lysis of Moloney virus-transformed lymphocytes: presence of viral antigen, accessibility to antibody, and complement activation.
    Proc Natl Acad Sci U S A. 1971 Oct;68(10):2584-8 PMID: 4944633
  119. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    J Immunol. 1986 Apr 15;136(8):2999-3005 PMID: 3958488
  120. Mechanism of cytolysis by complement.
    Proc Natl Acad Sci U S A. 1972 Oct;69(10):2954-8 PMID: 4117012
  121. Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C.
    J Immunol. 1978 Mar;120(3):895-901 PMID: 632591
  122. Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.
    Immunochemistry. 1969 May;6(3):391-403 PMID: 5786933
  123. Effect of antibody and complement on permeability control in ascites tumor cells and erythrocytes.
    J Exp Med. 1959 Nov 1;110:699-713 PMID: 13851485
  124. Reversible injury of cultured rat oligodendrocytes by complement.
    Immunology. 1989 Aug;67(4):441-6 PMID: 2767708
  125. Deposition of the membrane attack complex of complement in bullous pemphigoid.
    J Invest Dermatol. 1984 Feb;82(2):132-5 PMID: 6363566
  126. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis.
    Kidney Int. 1987 Mar;31(3):820-9 PMID: 3573542
  127. Effect of the late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation.
    Int Arch Allergy Appl Immunol. 1987;82(3-4):317-20 PMID: 3494679
  128. Cytokines as inflammatory mediators.
    Br Med Bull. 1987 Apr;43(2):350-70 PMID: 3319033
  129. Homologous species restriction in lysis of erythrocytes by terminal complement proteins.
    Proc Natl Acad Sci U S A. 1981 Aug;78(8):5118-21 PMID: 6946459
  130. Rapid stimulation of chemiluminescence in rat polymorphonuclear leucocytes caused by anti-cell antibody plus complement.
    Biochem Soc Trans. 1980 Dec;8(6):723-5 PMID: 7461263
  131. How is the level of free arachidonic acid controlled in mammalian cells?
    Biochem J. 1982 Apr 15;204(1):3-16 PMID: 6810878
Article Info
Journal
The Biochemical journal
Abbr.
Biochem J
ISSN
0264-6021
DOI
10.1042/bj2640001
Published
1989-11-15
Pages
1-14
Language
English
Region
England
NLM ID
2984726R
PMCID
PMC1133540
Subset
IM
Grants
Wellcome Trust · United Kingdom
External Links
PubMed source DOI: 10.1042/bj2640001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2